J. Thomas Hannich
YOU?
Author Swipe
View article: Purine nucleobases enhance CD8<sup>+</sup> T cell effector function
Purine nucleobases enhance CD8<sup>+</sup> T cell effector function Open
During antiviral immune responses, activated immune cells remodel metabolic pathways towards uptake and utilization of biosynthetic and bioenergetic metabolites. Concurrently, viral infections alter metabolic environments, impacting metabo…
View article: The solute carrier superfamily interactome
The solute carrier superfamily interactome Open
View article: Metabolic mapping of the human solute carrier superfamily
Metabolic mapping of the human solute carrier superfamily Open
View article: Loss of SPHK1 fuels inflammation to drive KRAS-mutated lung adenocarcinoma
Loss of SPHK1 fuels inflammation to drive KRAS-mutated lung adenocarcinoma Open
Inflammation is a widely recognized key contributor to KRAS-driven lung adenocarcinoma (LUAD). Tumor-associated macrophages (TAM) are an integral part of the tumor microenvironment and create a supportive niche that sustains inflammation-d…
View article: Functional profiling reveals a non-enzymatic role of NUDT5 in repressing purine <i>de novo</i> synthesis
Functional profiling reveals a non-enzymatic role of NUDT5 in repressing purine <i>de novo</i> synthesis Open
Folate metabolism is intricately linked to purine de novo synthesis through the incorporation of folate-derived one-carbon units into the purine scaffold. Here, we investigate the chemical and genetic dependencies caused by mutations in th…
View article: The solute carrier superfamily interactome
The solute carrier superfamily interactome Open
Solute carrier (SLC) transporters form a protein superfamily that enables transmembrane transport of diverse substrates including nutrients, ions and drugs. There are about 450 different SLCs, residing in a variety of subcellular membranes…
View article: Metabolic mapping of the human solute carrier superfamily
Metabolic mapping of the human solute carrier superfamily Open
Solute carrier (SLC) transporters govern most of the chemical exchange across cellular membranes and are integral to metabolic regulation, which in turn is linked to cellular function and identity. Despite their key role, individual functi…
View article: Alkylamine-tethered molecules recruit FBXO22 for targeted protein degradation
Alkylamine-tethered molecules recruit FBXO22 for targeted protein degradation Open
Targeted protein degradation (TPD) relies on small molecules to recruit proteins to E3 ligases to induce their ubiquitylation and degradation by the proteasome. Only a few of the approximately 600 human E3 ligases are currently amenable to…
View article: Orpinolide disrupts a leukemic dependency on cholesterol transport by inhibiting OSBP
Orpinolide disrupts a leukemic dependency on cholesterol transport by inhibiting OSBP Open
View article: Discovery of Molecular Glue Degraders via Isogenic Morphological Profiling
Discovery of Molecular Glue Degraders via Isogenic Morphological Profiling Open
Molecular glue degraders (MGDs) are small molecules that degrade proteins of interest via the ubiquitin-proteasome system. While MGDs were historically discovered serendipitously, approaches for MGD discovery now include cell-viability-bas…
View article: Pharmacological perturbation of the phase-separating protein SMNDC1
Pharmacological perturbation of the phase-separating protein SMNDC1 Open
View article: Paralog-dependent isogenic cell assay cascade generates highly selective SLC16A3 inhibitors
Paralog-dependent isogenic cell assay cascade generates highly selective SLC16A3 inhibitors Open
View article: Systemic Inflammation and Normocytic Anemia in DOCK11 Deficiency
Systemic Inflammation and Normocytic Anemia in DOCK11 Deficiency Open
Germline hemizygous loss-of-function mutations affecting the actin regulator DOCK11 were shown to cause a previously unknown inborn error of hematopoiesis and immunity characterized by severe immune dysregulation and systemic inflammation,…
View article: Biallelic <i>NFATC1</i> mutations cause an inborn error of immunity with impaired CD8+ T-cell function and perturbed glycolysis
Biallelic <i>NFATC1</i> mutations cause an inborn error of immunity with impaired CD8+ T-cell function and perturbed glycolysis Open
The nuclear factor of activated T cells (NFAT) family of transcription factors plays central roles in adaptive immunity in murine models; however, their contribution to human immune homeostasis remains poorly defined. In a multigenerationa…
View article: Supplementary Movie S1C from Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma
Supplementary Movie S1C from Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma Open
Cells pre-treated for 3h with 20 µM nelfinavir.
View article: Data from Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma
Data from Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma Open
The HIV-protease inhibitor nelfinavir has shown broad anticancer activity in various preclinical and clinical contexts. In patients with advanced, proteasome inhibitor (PI)–refractory multiple myeloma, nelfinavir-based therapy resulted in …
View article: Supplementary Movie S1B from Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma
Supplementary Movie S1B from Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma Open
Cells pre-treated for 3h with 10 µM brefeldin A
View article: Supplementary Data from Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma
Supplementary Data from Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma Open
Supplementary Methods, figures and tables
View article: Table S4 from Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma
Table S4 from Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma Open
All identified binding partners of nelfinavir across multiple cell lines
View article: Supplementary Movie S1B from Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma
Supplementary Movie S1B from Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma Open
Cells pre-treated for 3h with 10 µM brefeldin A
View article: Supplementary Movie S1A from Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma
Supplementary Movie S1A from Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma Open
Control cells, treated only with biotin
View article: Supplementary Movie S1A from Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma
Supplementary Movie S1A from Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma Open
Control cells, treated only with biotin
View article: Supplementary Data from Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma
Supplementary Data from Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma Open
Supplementary Methods, figures and tables
View article: Supplementary Movie S1C from Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma
Supplementary Movie S1C from Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma Open
Cells pre-treated for 3h with 20 µM nelfinavir.
View article: Table S4 from Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma
Table S4 from Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma Open
All identified binding partners of nelfinavir across multiple cell lines
View article: Data from Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma
Data from Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma Open
The HIV-protease inhibitor nelfinavir has shown broad anticancer activity in various preclinical and clinical contexts. In patients with advanced, proteasome inhibitor (PI)–refractory multiple myeloma, nelfinavir-based therapy resulted in …
View article: Orpinolide disrupts a leukemic dependency on cholesterol transport by inhibiting the oxysterol-binding protein OSBP
Orpinolide disrupts a leukemic dependency on cholesterol transport by inhibiting the oxysterol-binding protein OSBP Open
Metabolic alterations in cancer precipitate in associated dependencies that can be therapeutically exploited. To meet this goal, natural product inspired small molecules can provide a resource of invaluable chemotypes. Here, we identify or…
View article: Ceramide biosynthesis is critical for establishment of the intracellular niche of Toxoplasma gondii
Ceramide biosynthesis is critical for establishment of the intracellular niche of Toxoplasma gondii Open
View article: Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma
Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma Open
Antiapoptotic Bcl-2 family members have recently (re)emerged as key drug targets in cancer, with a tissue- and tumor-specific activity profile of available BH3 mimetics. In multiple myeloma, MCL-1 has been described as a major gatekeeper o…
View article: Patched regulates lipid homeostasis by controlling cellular cholesterol levels
Patched regulates lipid homeostasis by controlling cellular cholesterol levels Open
Hedgehog (Hh) signaling is essential during development and in organ physiology. In the canonical pathway, Hh binding to Patched (PTCH) relieves the inhibition of Smoothened (SMO). Yet, PTCH may also perform SMO-independent functions. Whil…